Solid Biosciences (SLDB) Income from Non-Controlling Interests (2017)
Solid Biosciences (SLDB) posted Income from Non-Controlling Interests of -$1.1 million for Q1 2017.
Powered by 
Analysis
Solid Biosciences (SLDB) Income from Non-Controlling Interests (2017) Analysis & Trends
Solid Biosciences has reported Income from Non-Controlling Interests for 1 years, with the latest figure at -$1.1 million in Q1 2017.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to -$1.1 million in Q1 2017, while the trailing twelve-month figure through Dec 2017 was -$1.1 million (changed N/A YoY) and the FY2017 annual result came in at -$1.1 million, up 52.55% from the prior year.
- Income from Non-Controlling Interests steadied at -$1.1 million in Q1 2017 per SLDB's latest filing.
- Over five years, Income from Non-Controlling Interests peaked at -$1.1 million in Q1 2017 and troughed at -$1.1 million in Q1 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Solid Biosciences | 1.48 Bn | 1.48 Bn | - | - |